Format

Send to

Choose Destination
See comment in PubMed Commons below
Target Oncol. 2010 Mar;5(1):59-63. doi: 10.1007/s11523-010-0133-x. Epub 2010 Mar 23.

Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.

Author information

1
Division of Hematology/Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA. wang2x2@ucmail.uc.edu

Abstract

Hepatocellular carcinoma (HCC) is a highly aggressive cancer. For patients who are diagnosed with advanced stage disease that are not surgical candidates, the disease is universally lethal. Advance has been made to extend survival with molecular target therapy, but durable complete responses are extremely rare. We report an unusual case where a 74-year-old patient with unresectable HCC received eight months of reduced-dose of sorafenib, a tyrosine kinase inhibitor, and achieved a durable complete remission. At the most recent follow up, he remains in remission 16 months after cessation of treatment, without clinical or imaging evidence of disease recurrence.

PMID:
20309643
DOI:
10.1007/s11523-010-0133-x
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center